ANCA positive systemic necrotising vasculitis MPO or PR3 ANCA-positive systemic necrotising Qualifying Criteria Qualifying criteria have been defined to expand failing to respond to corticosteroids and vasculitis with both of the following: diagnostic requirements and gather data to be cytotoxic immunosuppression used as a comparison (to ensure response to Ig) should patients relapse and require further Current (or within the previous six Evidence of active MPO or PR3 positive treatment in the future. (A) months) standard cytotoxic vasculitis confirmed by serology and an ANCA level above the normal reference range immunosuppressive ANCA-vasculitis unless negative ANCA level with active regimens; vasculitis AND AND Persistent active disease. At least two reactive indicators when assessed by Birmingham Vasculitis Activity Score (BVAS) version 3 (v3) (score > 5), Erythrocyte Sedimentation Rate (ESR) (score >5) and protein (CRP) (score >6). AND Persistent disease despite standard Corticosteroid therapy for 6 months unless steroid therapy is contraindicated Requirements consistent with the original criteria have been used and revised to include AND rituximab treatment (if available) and steroid treatment. The Immunosuppressant therapy A of Rituximab has failed to demonstrate a options are : response unless Rituximab is inaccessible or Cyclophosphamide contraindicated Azathioprine Mycophenolate AND Methotrexate At least two other immunosuppressant agents have been trialled in addition to steroids and
Qualifying Criteria MPO or PR3 ANCA-positive systemic necrotising vasculitis with both of the following: Current (or within the previous six months) standard cytotoxic immunosuppressive ANCA-vasculitis regimens; AND Persistent active disease. ANCA positive systemic necrotising vasculitis failing to respond to corticosteroids and cytotoxic immunosuppression Evidence of active MPO or PR3 positive vasculitis confirmed by serology and an ANCA level above the normal reference range unless negative ANCA level with active vasculitis AND At least two reactive indicators when assessed by Birmingham Vasculitis Activity Score (BVAS) version 3 (v3) (score > 5), Erythrocyte Sedimentation Rate (ESR) (score >5) and protein (CRP) (score >6). AND Persistent disease despite standard Corticosteroid therapy for 6 months unless steroid therapy is contraindicated AND A of Rituximab has failed to demonstrate a response unless Rituximab is inaccessible or contraindicated AND At least two other immunosuppressant agents have been trialled in addition to steroids and Qualifying criteria have been defined to expand diagnostic requirements and gather data to be used as a comparison (to ensure response to Ig) should patients relapse and require further treatment in the future. (A) Requirements consistent with the original criteria have been used and revised to include rituximab treatment (if available) and steroid treatment. The Immunosuppressant therapy options are : Cyclophosphamide Azathioprine Mycophenolate Methotrexate
anti-neutrophil-cytoplasmic-antibody%28anca%29.DOCX